The Latest Cardiac and Vascular News
– New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring – TOKYO, Sept. 18, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced…
WASHINGTON, Sept. 10, 2024 /PRNewswire/ — Novel device-based therapies may overcome limitations of pharmacologic therapies for some patients living with heart failure (HF), indicating that a synergistic approach between the two therapies is ideal for implementation of guideline directed…
May 13, 2024 09:28 AM Eastern Daylight Time CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that a new analysis of data from the remedē® System Pivotal Trial suggests favorable outcomes for […]
TOKYO–(BUSINESS WIRE)–Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two patients in the Phase 1/2 clinical trial (LAPiS Study) of HS-001 in combination with coronary artery bypass grafting […]
LONDON, July 30, 2018 /PRNewswire/ — Stem Cell Therapies in CVMDSummaryRegenerative medicine could potentially cure diseases and may replace palliative treatments for chronic diseases.Stem cells in particular have been studied for their regenerative properties: their potential to repair or replace damaged or diseased […]
NEW YORK and MELBOURNE, Australia, Dec. 21, 2017 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its novel mesenchymal precursor cell (MPC) therapy […]
ORANGEBURG, New York and STUTTGART, Germany, December 18, 2017 /PRNewswire/ — The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure. The announcement was made on December 12, 2017 by Impulse Dynamics’ CEO, Dr. Simos Kedikoglou. “This is a […]
HOUSTON–(BUSINESS WIRE)–October 26, 2017– CorInnova Inc., an emerging medical device company developing novel technology for the treatment of Heart Failure, announced today three milestone events: (1) the Company has received notice of allowance of a seminal patent to protect its intellectual […]
DUBLIN – September 27, 2017 – Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for its HeartWare(TM) HVAD(TM) System as a destination therapy for patients with advanced heart failure who are not candidates for heart transplants. […]
SAN RAMON, Calif. and CAMBRIDGE, England, Aug. 21, 2017 /PRNewswire/ — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced enrollment of the first patient in the international arm of the ALIVE pivotal clinical trial. The […]
